Hematopoietic growth factors in cancer patients with invasive fungal infections

  • F. Offner


Hematopoietic growth factors have been used in prophylaxis and treatment of neutropenic febrile episodes. Granulocyte colony-stimulating factor (G-CSF) and granulocyte macrophage colony-stimulating factor (GM-CSF) are the most common growth factors in clinical use. Both successfully shorten the duration of neutropenia following myelosuppressive or myeloablative chemotherapy. The influence of G-CSF and GM-CSF on documented infections and mortality from infections is less obvious. There is no clear evidence that treatment with growth factors reduces the incidence of fungal infections. Since mortality is not affected, considerations of morbidity and cost effectiveness currently dominate the indication for use of growth factors. At current costs, their use is indicated in prophylaxis when the likelihood of developing neutropenic febrile episodes following chemotherapy is 40% or more.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bodey G, Bueltmann B, Duguid W, Gibbs D, Hanak H, Hotchi M, Mall G, Martino P, Meunier F, Milliken S, Naoe S, Okudaira M, Scevola D, van't Wout J: Fungal infections in cancer patients: an international autopsy survey. Clinical Infectious Diseases 1994, 18: 525–532.Google Scholar
  2. 2.
    Walsh TJ, Hiemenz J, Pizzo PA: Evolving risk factors for invasive fungal infections: all neutropenic patients are not the same. Clinical Infectious Diseases 1994, 18: 793–798.Google Scholar
  3. 3.
    Schwartz RS, Mackintosh FR, Schrier SL, Greenberg PL: Multivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myelogenous leukemia. Cancer 1984, 53: 411–419.Google Scholar
  4. 4.
    Bodey GP, Buckley M, Sathe YS: Quantitative relationship between circulating leukocytes and infection in patients with leukemia. Annals of Internal Medicine 1966, 64: 328–340.Google Scholar
  5. 5.
    Maksymiuk AN, Thongprasert S, Hopfer R, Luna M, Fainstein V, Bodey GP: Systemic candidiasis in cancer patients. American Journal of Medicine 1984, 77, Supplement 4D: 20–27.Google Scholar
  6. 6.
    Lieschke J, Burgess AW: Granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor (parts I and II). New England Journal of Medicine 1992, 327: 28–35, 99–106.Google Scholar
  7. 7.
    Harmenberg J, Höglund M, Hellström-Lindberg E: G and GM-CSF in oncology and oncological haematology. European Journal of Haematology 1994, 52: 1–28.Google Scholar
  8. 8.
    Lord BI, Gurney H, Chang J, Thatcher N, Growther D, Dexter TM: Haematopoietic cell kinetics in humans trated with rGM-CSF. International Journal of Cancer 1992, 50: 26–31.Google Scholar
  9. 9.
    Lord BI, Bronchud MM, Owens S: The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proceedings of the National Academy of Sciences of the USA 1989, 86: 9499–9503.Google Scholar
  10. 10.
    Gabrilove JL, Jakubowski A, Fain K: Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. Journal of Clinical Investigation 1988, 82: 1454–1461.Google Scholar
  11. 11.
    Duhrsen U, Villeval JL, Boyd J, Kamourakis G, Morstyn G, Metcalf D: Effects of recombinant human granulocyte cology-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988, 72: 2074–2081.Google Scholar
  12. 12.
    Steward WP, Scarffe JY, Austin R: Recombinant human granulocyte macrophage colony stimulating factor (rh GM-CSF) given as daily short infusions-a phase I dosetoxicity study. British Journal of Cancer 1989, 59: 142–145.Google Scholar
  13. 13.
    Fleischmann J, Golde DW, Weisbart RH, Gasson JC: Granulocyte macrophage colony-stimulating factor enhances phagocytosis of bacteria by human neutrophils. Blood 1986, 68: 708–711.Google Scholar
  14. 14.
    Roilides E, Walsh TJ, Pizzo PA, Rubin M: Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. Journal of Infectious Diseases 1991, 163: 579–583.Google Scholar
  15. 15.
    Yuo A, Kitagawa S, Ohsaka A: Recombinant human granulocyte colony-stimulating factor as an activator of human granulocytes: potentiation of responses triggered by receptor-mediated agonists and stimulation of C3bi-receptor expression and adherence. Blood 1989, 74: 2144–2149.Google Scholar
  16. 16.
    Griffin JD, Spertini O, Ernst TJ: Granulocyte-macrophage colony-stimulating factor and other cytokines regulate surface expression of the leukocyte adhesion molecular-1 on human neutrophils, monocytes and their precursors. Journal of Immunology 1990, 145: 576–584.Google Scholar
  17. 17.
    Spertini O, Kansas GS, Munro JM, Griffin JD, Tedder TF: Regulation of leukocyte migration by activation of the leukocyte adhesion molecule-1 (LAM-1) selectin. Nature 1991, 349: 961–964.Google Scholar
  18. 18.
    Myrvang Høgåsen AK, Abrahamsen TG: Increased C3 production in human monocytes after stimulation withCandida albicans is suppressed by granulocyte-macrophage colony-stimulating factor. Infection and Immunity 1993, 61: 1779–1785.Google Scholar
  19. 19.
    Nathan CF: Respiratory burst in adherent human neutrophils: triggering by colony-stimulating factors CSF-GM and CSF-G. Blood 1989, 73: 301–306.Google Scholar
  20. 20.
    Ohsaka A, Kitagawa S, Sakamoto S: In vivo activation of human neutrophil functions by administration of recombinant granulocyte colony-stimulating factor in patients with malignant lymphoma. Blood 1989, 74: 2743–2748.Google Scholar
  21. 21.
    Fabian I, Baldwin GC, Golde DN: Biosynthetic granulocyte-macrophage colony-stimulating factor enhances neutrophil cytotoxicity towards haman leukemia cells. Leukemia 1987, 1: 613–617.Google Scholar
  22. 22.
    Fukunaga R, Ishizaka-Ikeda E, Nagata S: Growth and differentiation signals mediated by different regions in the cytoplasmic domain of granulocyte colony-stimulating factor receptor. Cell 1993, 74: 1079–1087.Google Scholar
  23. 23.
    Arnaout MA, Wang EA, Clark SC, Sieff CA: Human granulocyte-macrophage colony-stimulating factor increases cell-to-cell adhesion and surface expression of adhesion-promoting surface glycoproteins on mature granulocytes. Journal of Clinical Investigation 1986, 78: 597–601.Google Scholar
  24. 24.
    Peters WP, Stuart A, Affronti ML, Kim CS, Coleman RE: Neutrophil migration is defective during recombinant human granulocyte-macrophage colony-stimulating factor infusion after autologous bone marrow transplantation in humans. Blood 1988, 72: 1310–1315.Google Scholar
  25. 25.
    Addison IE, Johnson B, Devereux S, Goldstone AN, Linch DC: Granulocyte-macrophage colony-stimulating factor may inhibit neutrophil migration in vivo. Clinical Experimental Immunology 1989, 76: 149–153.Google Scholar
  26. 26.
    Heidenreich S, Gong JH, Schmidt A, Nain M, Gemsa D: Macrophage activation by granulocyte-macrophage colony-stimulating factor. Priming for enhanced release of tumor necrosis factor alpha and prostaglandin E2. Journal of Immunology 1989, 143: 1198–1205.Google Scholar
  27. 27.
    Polak WA: Protective effect of human granulocyte colony stimulating factor (hG-CSF) onCandida infections in normal and immunosuppressed mice. Mycoses 1992, 34: 109–118.Google Scholar
  28. 28.
    Lechner AJ, Lamprech KE, Potthoff LH, Tredway TL, Matuschak GM: Recombinant GM-CSF reduces lung injury and mortality during neutropenicCandida sepsis. American Journal of Physiology 1994, 266: 561–568.Google Scholar
  29. 29.
    Nelson S: Role of granulocyte colony-stimulating factor in the immune response to acute bacterial infection in the non-neutropenic host: an overview. Clinical Infectious Diseases 1994, 18, Supplement 2: 197–204.Google Scholar
  30. 30.
    Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara J, Kris M, Grous J, Picozzi V, Rausch G, Smith R, Gradishan W, Yahanda A, Vincent M, Stewart M, Glaspy J: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. New England Journal of Medicine 1991, 325: 164–170.Google Scholar
  31. 31.
    Trillet-Lenoir V, Green J, Manegold C, Van Pawel J, Gatzemeier V, Lebeau B, Depierre A, Johnson P, Decoster G, Tomita D, Ewen C: Recombinant granulocyte colonystimulating factor reduces the infectious complications of cytotoxic chemotherapy. European Journal of Cancer 1993, 29A: 319–324.Google Scholar
  32. 32.
    Pettengell R, Gurney H, Radford JA, Deakin DP, Wilkinson PM, Kane K, Bentley J, Crowther D: Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma. A randomized controlled trial. Blood 1992, 80: 1430–1434.Google Scholar
  33. 33.
    Gisselbrecht C, Coiffier B, Lepage E: Placebo-controlled phase III trial of lenograstim in aggressive non-Hodgkin's lymphoma. Annals of Oncology 1994, 91: 454.Google Scholar
  34. 34.
    Gerhartz JJ, Engehard M, Meusers P, Brittinger G, Wilmanns W, Schlimok G, Mueller P, Huhn D, Musch R, Siegert W, Gerhartz D, Hartlapp JH, Thiel E, Huber C, Peschl C, Spann W, Emmerich B, Schadek C, Westerhausen M, Pees HW, Radtke H, Engert A, Terhardt E, Schick H, Binder T, Fuchs R, Hasford J, Brandmaier R, Stern AC, Jones TC, Eherlich HJ, Stein H, Parwaresch M, Tiemann M, Lennert K: Randomized double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood 1993, 82: 2329–2339.Google Scholar
  35. 35.
    Nichols C, Bajorin D, Schmoll HJ: VIP chemotherapy with/without GM-CSF for poor risk, relapsed or refractory germ cell tumors. Proceedings of the American Society for Clinical Oncology 1991, 10: 167.Google Scholar
  36. 36.
    Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, Lee EJ, Moore JO, Powell BL, Schiffer CA (for the Cancer and Leukemia Group B): Granulocytemacrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. New England Journal of Medicine 1995, 332: 1671–1677.Google Scholar
  37. 37.
    Dombret H, Chastang C, Fenaux P, Reiffers J. Bordessoule D, Bouabdallah R, Mandelli F, Ferrant A, Auzanneau G, Tilly H, Yver A, Degos L (for the AML Cooperative Study Group): A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. New England Journal of Medicine 1995, 332: 1678–1682.Google Scholar
  38. 38.
    Maher DW, Lieschke GJ, Green M, Bishop J, Stuart-Harris R, Wolf M, Sheridan WP, Kefford RF, Cebon J, Olver I, McKendrick J. Toner G, Bradstock K, Lieschke M, Cruickshank S, Tomita DK, Hoffman EW, Fox RM, Morstyn G: Filgrastim in patients with chemotherapy-induced febrile neutropenia. Annals of Internal Medicine 1994, 121: 492–501.Google Scholar
  39. 39.
    Biesma G, DeVries EG, Willemse PHB, Sluiter WJ, Postmus PE, Limburg PC, Stern AC, Vellenga E: Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related colony-stimulating factor in patients with chemotherapy-related leukopenia and fever. European Journal of Cancer 1990, 26: 932–936.Google Scholar
  40. 40.
    Riikonen P, Saarinen V, Mäkipernaa A, Hovi L, Kamulainen A, Pihkala J, Jalanko H: Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebocontrolled study in children. Pediatric Infectious Disease Journal 1994, 13: 197–202.Google Scholar
  41. 41.
    Mayordomo JI, Rivera F, Diaz-Purente MT, Llanes P, Cortes-Funes H: Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. Journal of the National Cancer Institute 1993, 85: 1251–1252.Google Scholar
  42. 42.
    Nemunaitis J, Rabinowe SN, Singer JW, Buchner CD, Appelbaum F: Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. New England Journal of Medicine 1991, 324: 1773–1778.Google Scholar
  43. 43.
    Link H, Boogaerts MA, Carella AM: A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high dose chemotherapy and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma. Blood 1992, 80: 2188–2195.Google Scholar
  44. 44.
    Stahel RA, Jost LM, Cerny TH, Pichert G, Honegger H, Tobber A, Jacky E, Fey M, Platzer E: Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone-marrow transplantation for high-risk lymphoid malignancies. Journal of Clinical Oncology 1994, 12: 1931–1939.Google Scholar
  45. 45.
    Masaoka T, Takaku F, Kato S: Recombinant human granulocyte colony stimulating factor in allogeneic bone marrow transplantation. Experimental Hematology 1989, 1047–1050.Google Scholar
  46. 46.
    Anasetti C, Anderson G, Appelbaum FR, Buchner CD, Martin PH, Nemunaitis J, Singer J, Storb R, Sullivan KM, Thomas ED, Hansen JA: Phase III study of rh GM-CSF in allogeneic marrow transplantation from unrelated donors. Blood 1993, 82, Supplement 1: 454.Google Scholar
  47. 47.
    de Witte T, Gratwohl A, Van der Lely N: Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil T-cell-depleted bone marrow transplantation. Blood 1992, 79: 1359–1365.Google Scholar
  48. 48.
    Ozer H: Hematopoietic colony-stimulating factors. Clinical practice guidelines. Proceedings of the American Society of Clinical Oncology 1995, Educational Symposia: 221–231.Google Scholar
  49. 49.
    Lyman GH, Lyman CG, Sanderson RA, Balducci L: Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. Journal of the National Cancer Institute 1993, 85: 488–493.Google Scholar
  50. 50.
    Offner F, Schoch G, Fisher L, Martin P: Mortality hazard as related to the duration of neutropenia after marrow transplantation. Blood 1994, 84, Supplement 1: 487.Google Scholar
  51. 51.
    Mempel K, Pietsch T, Menzel T, Zeidler C, Welte K: Increased serum levels of granulocyte colony-stimulating factor in patients with severe congenital neutropenia. Blood 1991, 77: 1919–1922.Google Scholar
  52. 52.
    Kawakami M, Tsutsumi H, Kumakawa T, Abe H, Hirai M, Kurosawa S, Mori M, Fukushima M: Levels of serum granulocyte colony-stimulating factor in patients with infections. Blood 1990, 76: 1962–1964.Google Scholar
  53. 53.
    Cebon J, Layton JE, Maher D, Morstyn G: Endogenous haemopoletic growth factors in neutropenia and infection. British Journal of Haematology 1994, 86: 265–274.Google Scholar
  54. 54.
    Morstyn G, Campbell L, Souza LM: Effect of granulocyte colony-stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988, i: 667–672.Google Scholar
  55. 55.
    Bodey GP, Anaissie E, Guttermans J, Vadhan-Raj S: Role of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection. European Journal of Clinical Microbiology & Infectious Diseases 1994, 13, Supplement 2: 18–22.Google Scholar

Copyright information

© MMV Medizin Verlag GmbH 1997

Authors and Affiliations

  • F. Offner
    • 1
  1. 1.Department of HematologyUniversity Hospital of GhentGhentBelgium

Personalised recommendations